Skip to content

Beta Blocker Therapy for Severe Traumatic Brain Injury

Beta Blocker Therapy for Severe Traumatic Brain Injury: A randomized controlled trial Project Protocol - Beta blocker

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/08/035637
Enrollment
120
Registered
2021-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S065- Traumatic subdural hemorrhage

Interventions

Intervention1: Propranolol: Patients of moderate and severe TBI who meet eligibility criteria will be randomized and those in test group will be given beta-blocker drug (propanolol) immediately after

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients who present within 24 hours of moderate and severe traumatic brain injury who have: a)Glasgow Coma Scale (GCS) score of b)Age: 18 to 60 years

Exclusion criteria

Exclusion criteria: • Pre-existing condition o Heart disease o Cardiac dysrhythmia o Allergy to study drugs • Brain-related o Penetrating brain injury o Pre-existing brain dysfunction • Physiologic o Spinal cord injury o Myocardial injury o Severe liver disease o Current use of β-blocker and/or α2-agonist o Withdrawal of care expected in 48 h • Demographic o Prisoners o Pregnant women o Unable to follow-up through final visit

Design outcomes

Primary

MeasureTime frame
To determine the efficacy of beta blockers in reducing the mortality of hospitalized severe traumatic brain injury (TBI) patientsTimepoint: AT the time of discharge from hospital and 3 and 6 months after trauma.

Secondary

MeasureTime frame
â?¢ To assess the improvement in dysautonomia clinically.Timepoint: 6 months;â?¢ To determine the efficacy of beta blockers in improving the functional outcomes and the quality of life of moderate and severe TBI patient at 6 months post injury Timepoint: 6 months

Countries

India

Contacts

Public ContactKanwaljeet Garg

All India Institute of Medical Sciences

kanwaljeet@aiims.edu9868398224

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026